Literature DB >> 3007065

[Increase in the prevalence of antibodies against LAV/HTLV III in drug addicts in West Germany].

G Zoulek, L Gürtler, J Eberle, B Lorbeer, F Deinhardt.   

Abstract

Sera obtained from 927 drug addicts in 1983 to 1985 were tested for antibodies against LAV/HTLV-III. There was a steadily rising proportion of positive results: 10.1% in 1983, 17.6% in 1984 and 23.9% in 1985. In each year the prevalence of anti-LAV/HTLV-III was higher among female than male addicts. No increased proportion of positive results was demonstrable in relation to age. Among 152 sera from 1983/84, hepatitis-B markers were found in 72 (43.7%), of whom 10 (14%) were also anti-LAV/HTLV-III positive. Among hepatitis-B marker-negative sera there were 8 (6%) which were also anti-LAV/HTLV-III positive. The prevalence of anti-LAV/HTLV-III in drug addicts in prisons, rehabilitation centres, hospitals and medical practices was similar. There is a danger that prostitution by addicts for obtaining drugs will cause a penetration of LAV/HTLV-III in the rest of the population.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007065     DOI: 10.1055/s-2008-1068490

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

1.  Antibody prevalence of parenterally transmitted viruses (HIV-1, HTLV-I, HBV, HCV) in Austrian intravenous drug users.

Authors:  J Pont; C Neuwald; G Salzner
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

2.  HIV infection in intravenous drug abusers in Berlin: risk factors and time trends.

Authors:  K Stark; R Müller; I Guggenmoos-Holzmann; S Deininger; E Meyer; U Bienzle
Journal:  Klin Wochenschr       Date:  1990-04-17

3.  Risk factors for HIV infection in German i.v. drug abusers. Clinical, serological and epidemiological features.

Authors:  G Harms; U Laukamm-Josten; U Bienzle; I Guggenmoos-Holzmann
Journal:  Klin Wochenschr       Date:  1987-04-15

Review 4.  Transmission of human immunodeficiency virus (HIV/HTLV-III/LAV): a review.

Authors:  M van der Graaf; R J Diepersloot
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.